When did Candel Therapeutics, Inc. report Q4 2024 earnings?

Candel Therapeutics, Inc. (CADL) reported Q4 2024 earnings on March 13, 2025 before market open.

What were Candel Therapeutics, Inc.'s Q4 2024 revenue and EPS?

Candel Therapeutics, Inc. reported eps of $-0.40 for Q4 2024.

Did Candel Therapeutics, Inc. beat estimates in Q4 2024?

EPS missed the consensus estimate of $-0.23 by $0.17.

Where can I find Candel Therapeutics, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0000950170-25-038803) directly on SEC EDGAR. The filing index links above go to sec.gov.

Candel Therapeutics, Inc. CADL Q4 2024 Annual earnings

Reported March 13, 2025 · Before market open

EPS-$0.40Miss by $0.17

EPS estimate-$0.23

Next report

Aug 13, 2026 (In 2 weeks)

EPS estimate-$0.22

Financials

Q4 2024

Income statement

See full

Operating income-$8.1M+21.1%

Net income-$14.1M-26.8%

EPS (diluted)-$0.39-2.6%

Balance sheet

See full

Cash & equivalents$102.7M+190%

Total debt$11.7M+5.5%

Total equity$66.3M+420%

Total assets$106.9M+159%

Cash flow

See full

Operating cash flow-$5.8M+21.7%

CapEx$3.0K-93.6%

Free cash flow-$5.8M+22.1%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$386.05M+806%

Enterprise value$295.13M+1,511%

Returns & leverage

See full

Return on equity-139.6%+17.6pp

Debt / equity0.2×-0.7×

Current ratio2.8×+0.2×

Versus estimates

Diluted EPS

Q1 2026-$0.14Beat by $0.08 Q4 2025-$0.54Miss by $0.30 Q3 2025-$0.21Miss by $0.04 Q2 2025-$0.09Beat by $0.08 Q1 2025$0.13Beat by $0.37

Q4 2024-$0.40Miss by $0.17

Ask the moment Candel Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Candel Therapeutics, Inc. report Q4 2024 earnings?: Candel Therapeutics, Inc. (CADL) reported Q4 2024 earnings on March 13, 2025 before market open.
What were Candel Therapeutics, Inc.'s Q4 2024 revenue and EPS?: Candel Therapeutics, Inc. reported eps of $-0.40 for Q4 2024.
Did Candel Therapeutics, Inc. beat estimates in Q4 2024?: EPS missed the consensus estimate of $-0.23 by $0.17.
Where can I find Candel Therapeutics, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0000950170-25-038803) directly on SEC EDGAR. The filing index links above go to sec.gov.